How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
With ageing of the population, both the risks of cardiovascular disease (CVD) and cancer are increasing worldwide, and the risk factors (e.g. obesity, diabetes) are often shared between the two conditions. Thus, more subjects will also develop the two illnesses concurrently [...].
Willems RAL, Winckers K, Biesmans C, et al. Evolving data on cardiovascular complications in cancer. Thromb Res 2022;213:S87-S94. DOI: https://doi.org/10.1016/j.thromres.2022.01.003
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist 2017;22:199-2. DOI: https://doi.org/10.1634/theoncologist.2016-0214
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926-38. DOI: https://doi.org/10.1016/j.jacc.2017.06.047
Navi BB, Reiner AS, Kamel H, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019;133:781-9. DOI: https://doi.org/10.1182/blood-2018-06-860874
Falanga A, Leader A, Ambaglio C, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 2022;6:e750. DOI: https://doi.org/10.1097/HS9.0000000000000750
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.